Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 154 participants.
Also called NCT02426294
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 154 participants
- Registry
-
NCT02426294
-
- Other papers using this trial's data
- Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02426294. Randomized; no masking; primary purpose treatment. Start 2015-02 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Pusan National University Hospital
Record details
- Record id
cardio:ct-nct02426294- Content hash
43b84fe6d8d5979bb84c72c389be1d21d4f796d13dbfe33dae6c002fad8abc60